Oregon Public Employees Retirement Fund increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1.1% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 102,264 shares of the company’s stock after buying an additional 1,100 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Eli Lilly and were worth $8,416,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. BlackRock Inc. boosted its position in Eli Lilly and by 2,628.5% in the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock valued at $5,236,731,000 after buying an additional 59,978,664 shares during the last quarter. Norges Bank bought a new position in Eli Lilly and during the fourth quarter valued at approximately $658,856,000. Beutel Goodman & Co Ltd. bought a new position in Eli Lilly and during the first quarter valued at approximately $161,084,000. Vanguard Group Inc. boosted its position in Eli Lilly and by 3.3% in the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock valued at $5,769,694,000 after buying an additional 2,181,701 shares in the last quarter. Finally, Winslow Capital Management LLC boosted its position in Eli Lilly and by 79.7% in the first quarter. Winslow Capital Management LLC now owns 3,875,968 shares of the company’s stock valued at $326,008,000 after buying an additional 1,719,538 shares in the last quarter. 75.56% of the stock is currently owned by institutional investors.
Shares of Eli Lilly and Company (NYSE:LLY) traded up 0.10% during mid-day trading on Friday, reaching $83.10. 3,820,069 shares of the company’s stock traded hands. The stock has a market cap of $87.85 billion, a PE ratio of 35.96 and a beta of 0.35. The firm has a 50 day moving average price of $82.91 and a 200-day moving average price of $81.37. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $86.72.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.50%. The firm had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. During the same quarter last year, the business earned $0.86 earnings per share. The business’s revenue was up 7.8% on a year-over-year basis. On average, analysts predict that Eli Lilly and Company will post $4.15 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.50%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s dividend payout ratio is 90.04%.
Several equities analysts have recently commented on LLY shares. Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $92.00 price target on shares of Eli Lilly and in a report on Tuesday, May 16th. BMO Capital Markets set a $71.00 price objective on shares of Eli Lilly and and gave the stock a “sell” rating in a report on Tuesday, April 25th. Zacks Investment Research cut shares of Eli Lilly and from a “buy” rating to a “hold” rating in a report on Tuesday, April 18th. Credit Suisse Group reiterated an “outperform” rating and issued a $87.00 price objective on shares of Eli Lilly and in a report on Wednesday, April 19th. Finally, Argus cut shares of Eli Lilly and from a “buy” rating to a “hold” rating and upped their price objective for the stock from $64.18 to $81.00 in a report on Thursday, April 27th. They noted that the move was a valuation call. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the company. Eli Lilly and presently has an average rating of “Hold” and a consensus price target of $88.37.
In other news, SVP Enrique A. Conterno sold 25,000 shares of Eli Lilly and stock in a transaction dated Thursday, May 4th. The stock was sold at an average price of $82.76, for a total value of $2,069,000.00. Following the completion of the transaction, the senior vice president now owns 114,217 shares of the company’s stock, valued at approximately $9,452,598.92. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Michael J. Harrington sold 22,833 shares of Eli Lilly and stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $79.97, for a total value of $1,825,955.01. Following the completion of the transaction, the vice president now directly owns 62,056 shares of the company’s stock, valued at approximately $4,962,618.32. The disclosure for this sale can be found here. Insiders sold 474,733 shares of company stock worth $39,634,487 in the last 90 days. Company insiders own 0.20% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
